Matt Miksic
Stock Analyst at Barclays
(3.77)
# 724
Out of 5,044 analysts
293
Total ratings
59.92%
Success rate
4.72%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYK Stryker | Maintains: Overweight | $443 → $453 | $375.93 | +20.50% | 24 | Oct 22, 2025 | |
| ABT Abbott Laboratories | Maintains: Overweight | $159 → $162 | $126.61 | +27.95% | 30 | Oct 17, 2025 | |
| GEHC GE HealthCare Technologies | Initiates: Equal-Weight | $86 | $79.40 | +8.31% | 1 | Oct 13, 2025 | |
| COO The Cooper Companies | Initiates: Overweight | $85 | $71.75 | +18.47% | 1 | Oct 13, 2025 | |
| ALC Alcon | Initiates: Equal-Weight | $86 | $74.82 | +14.94% | 10 | Oct 13, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $133 → $136 | $100.97 | +34.69% | 19 | Oct 2, 2025 | |
| SENS Senseonics Holdings | Initiates: Overweight | $30 | $7.20 | +316.67% | 1 | Aug 27, 2025 | |
| HUMA Humacyte | Initiates: Overweight | $3.5 | $1.70 | +105.88% | 1 | Aug 27, 2025 | |
| LIVN LivaNova | Maintains: Equal-Weight | $55 → $58 | $53.86 | +7.69% | 8 | Aug 21, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $266 → $300 | $324.34 | -7.50% | 9 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $51 | $15.10 | +237.75% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $36 | $22.86 | +57.48% | 22 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $16.65 | +32.13% | 3 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $15.27 | +37.52% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $93 → $98 | $69.23 | +41.56% | 7 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $95 | $82.19 | +15.59% | 29 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $176 | $186.93 | -5.85% | 13 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $19 → $16 | $15.20 | +5.26% | 5 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $241 | $184.21 | +30.83% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $3.79 | +216.62% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $684 → $635 | $545.39 | +16.43% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $103 | $62.75 | +64.14% | 15 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $101.14 | +10.74% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $4.82 | +356.43% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $93.23 | +16.92% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $63.21 | +58.20% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $133.14 | +213.96% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $16.56 | +69.08% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $13.07 | +412.62% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $5.75 | +8,247.83% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $15.56 | +459.13% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.19 | +496.66% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $6.88 | +30.81% | 1 | Dec 12, 2016 |
Stryker
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $375.93
Upside: +20.50%
Abbott Laboratories
Oct 17, 2025
Maintains: Overweight
Price Target: $159 → $162
Current: $126.61
Upside: +27.95%
GE HealthCare Technologies
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $79.40
Upside: +8.31%
The Cooper Companies
Oct 13, 2025
Initiates: Overweight
Price Target: $85
Current: $71.75
Upside: +18.47%
Alcon
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $74.82
Upside: +14.94%
Boston Scientific
Oct 2, 2025
Maintains: Overweight
Price Target: $133 → $136
Current: $100.97
Upside: +34.69%
Senseonics Holdings
Aug 27, 2025
Initiates: Overweight
Price Target: $30
Current: $7.20
Upside: +316.67%
Humacyte
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $1.70
Upside: +105.88%
LivaNova
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $55 → $58
Current: $53.86
Upside: +7.69%
Insulet
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $266 → $300
Current: $324.34
Upside: -7.50%
Aug 8, 2025
Maintains: Overweight
Price Target: $53 → $51
Current: $15.10
Upside: +237.75%
Aug 4, 2025
Maintains: Overweight
Price Target: $41 → $36
Current: $22.86
Upside: +57.48%
Aug 4, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $16.65
Upside: +32.13%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $15.27
Upside: +37.52%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $93 → $98
Current: $69.23
Upside: +41.56%
Jul 25, 2025
Maintains: Overweight
Price Target: $90 → $95
Current: $82.19
Upside: +15.59%
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $165 → $176
Current: $186.93
Upside: -5.85%
Jun 9, 2025
Maintains: Equal-Weight
Price Target: $19 → $16
Current: $15.20
Upside: +5.26%
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $184.21
Upside: +30.83%
May 5, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $3.79
Upside: +216.62%
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $545.39
Upside: +16.43%
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $62.75
Upside: +64.14%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $101.14
Upside: +10.74%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $4.82
Upside: +356.43%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $93.23
Upside: +16.92%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $63.21
Upside: +58.20%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $133.14
Upside: +213.96%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $16.56
Upside: +69.08%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $13.07
Upside: +412.62%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $5.75
Upside: +8,247.83%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $15.56
Upside: +459.13%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.19
Upside: +496.66%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $6.88
Upside: +30.81%